THERAPY DOSSIER · th-a133a6f8910e

Genipin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL459016 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Genipin
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05755750 ↗PHASE3completed

Clinical and Ultrasonographic Evaluation of Intratendinous Genipin Injection in Horses With Superficial Digital Flexor Tendon Injuries

Superficial Digital Flexor Tendonitis

Enrolment: 74 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31805268 ↗2019Reported benefit

Protective effects of genipin on ethanol-induced acute gastric injury in mice by inhibiting NLRP3 inflammasome activation.

MouseChemical/toxinmale (per MeSH)Intragastric (oral)Pretreatment, given for 7 days before ethanol challenge

Model: Ethanol induced acute gastric injury, ethanol given for 1 hour

Oral genipin pretreatment reduced ethanol induced gastric mucosal damage, lowered oxidative stress and inflammatory cytokines and suppressed NLRP3 pathway protein expression.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…